Novo Nordisk A/S (NYSE:NVO) Shares Sold by Somerville Kurt F

Somerville Kurt F decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.0% in the second quarter, Holdings Channel reports. The fund owned 18,050 shares of the company’s stock after selling 2,000 shares during the period. Somerville Kurt F’s holdings in Novo Nordisk A/S were worth $921,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $49,039,000. Jennison Associates LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $33,951,000. Raymond James & Associates lifted its stake in shares of Novo Nordisk A/S by 83.8% in the 1st quarter. Raymond James & Associates now owns 1,174,105 shares of the company’s stock valued at $61,418,000 after purchasing an additional 535,302 shares during the period. Sphera Funds Management LTD. purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $20,924,000. Finally, Clearbridge Investments LLC lifted its stake in shares of Novo Nordisk A/S by 42.3% in the 1st quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock valued at $60,729,000 after purchasing an additional 344,989 shares during the period. Institutional investors own 7.12% of the company’s stock.

A number of research analysts have recently commented on NVO shares. UBS Group restated a “buy” rating and issued a $355.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, June 19th. Pareto Securities lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective for the company in a research report on Tuesday, June 11th. Deutsche Bank lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective for the company. in a research report on Thursday, June 20th. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a research report on Monday, July 15th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $111.58.

NVO stock traded up $0.15 on Friday, reaching $48.72. 1,285,362 shares of the company traded hands, compared to its average volume of 1,780,926. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market cap of $118.99 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.23 and a beta of 0.60. The firm’s fifty day simple moving average is $49.84.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.04. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. The company had revenue of $4.46 billion during the quarter, compared to analyst estimates of $4.35 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 2.43 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.